A case of AMMoL with 8/21 translocation and loss of the Y as probably secondary events.
The clinical, hematological, and cytogenetic characteristics of a male patient with AMMoL are described. Before treatment a clone with the complex karyotype 45,X,del(7)(q32), t(8;21)(q22;q22) was present in the bone marrow. During partial remission induced by cytostatics, the percentage of normal cells increased, and a cell line having a 46,XY,del(7)(q32) karyotype was found. After four therapy courses, when remission was complete, only chromosomally normal cells were seen. The cytogenetic data suggest that in this case the 8/21 translocation and loss of the Y chromosome were only secondary events.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000648:ultrastructure; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002904:Chromosomes, Human, 21-22 and Y; D002906:Chromosomes, Human, 6-12 and X; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D012730:Sex Chromosomes; D014178:Translocation, Genetic; D014998:Y Chromosome
D000970:Antineoplastic Agents